imgc936
mAbexperimentalADC
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 26, 2020 (NCT04622774)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- ADAM9INHIBITOR
ADAM9 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- maytansinoid
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04622774 | Phase 1 | Oct 26, 2020 | Immunogen, MacroGenics |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Immunogen | For profit | 1 | 1 | 1 | 2020 |
| MacroGenics | For profit | 1 | 0 | 1 | 2020 |
2 organizations
Page 1 / 1